Your browser doesn't support javascript.
loading
Low-molecular-weight fucoidan inhibits the proliferation of melanoma via Bcl-2 phosphorylation and PTEN/AKT pathway.
Park, Minji; Bang, Chulhwan; Yun, Won-Soo; Jeong, Yun-Mi.
Affiliation
  • Park M; T&R Biofab Co., Ltd., Seongnam-si, 13487, Korea.
  • Bang C; Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 02706, Korea.
  • Yun WS; Department of Mechanical Engineering, Tech University of Korea, Si-heung City, 15073, Korea.
  • Jeong YM; Department of Mechanical Engineering, Tech University of Korea, Si-heung City, 15073, Korea.
Oncol Res ; 32(2): 273-282, 2023.
Article de En | MEDLINE | ID: mdl-38186578
ABSTRACT
Fucoidan, a sulfate polysaccharide obtained from brown seaweed, has various bioactive properties, including anti-inflammatory, anti-cancer, anti-viral, anti-oxidant, anti-coagulant, anti-thrombotic, anti-angiogenic, and anti-Helicobacter pylori properties. However, the effects of low-molecular-weight fucoidan (LMW-F) on melanoma cell lines and three dimensional (3D) cell culture models are not well understood. This study aimed to investigate the effects of LMW-F on A375 human melanoma cells and cryopreserved biospecimens derived from patients with advanced melanoma. Ultrasonic wave was used to fragment fucoidan derived from Fucus vesiculosus into smaller LMW-F. MTT and live/dead assays showed that LMW-F inhibited cell proliferation in both A375 cells and patient-derived melanoma explants in a 3D-printed collagen scaffold. The PTEN/AKT pathway was found to be involved in the anti-melanoma effects of fucoidan. Western blot analysis revealed that LMW-F reduced the phosphorylation of Bcl-2 at Thr 56, which was associated with the prevention of anti-apoptotic activity of cancer cells. Our findings suggested that LMW-F could enhance anti-melanoma chemotherapy and improve the outcomes of patients with melanoma resistance.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Mélanome / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Oncol Res Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Mélanome / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Oncol Res Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article